DIRS.INFO The most relevant business & tech news

☆ Here's where to look for the next developments in the fight against Alzheimer's disease
▼ + stars: | 2023-01-17 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +10 min

The Centers for Disease Control and Prevention estimates 5.8 million Americans were living with the disease in 2020 . BIIB 6M mountain Biogen's stock is trading well above its lows Leqembi treats Alzheimer's disease by targeting amyloid-beta plaques in the brain. Attention shifts to Eli Lilly Shares of other Alzheimer's drug developers have often mirrored Biogen's moves. Small drug developers Smaller Alzheimer's drug developers have also been boosted by research developments. Still in an early stage of its research, Prothena has traded as a proxy for developments in Alzheimer's treatment.

☆ Eli Lilly is the best of both worlds — a recession-resistant stock with major growth potential
▼ + stars: | 2023-01-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

The year ahead is pivotal for Eli Lilly (LLY) as the pharmaceutical giant looks to advance drugs in its stellar pipeline. It's a dynamic that, in many ways, embodies the Club's thinking on Eli Lilly, one of our 10 core holdings . In the meantime, Eli Lilly is set to release Phase 3 data for a number of different studies in 2023. Eli Lilly has already asked U.S. regulators to expand the drug's approved uses to obesity, in addition to being sold as Mounjaro for type 2 diabetes. Traders work beneath monitors displaying Eli Lilly signage on the floor of the New York Stock Exchange.

Organizations: & $

☆ Jim Cramer's Investing Club meeting Tuesday: Microsoft, health care, Emerson Electric
▼ + stars: | 2023-01-10 | by ( Krystal Hur | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Reduce exposure to tech Stocks inched up on Tuesday, with the Nasdaq Composite rising 0.22% in midmorning trading. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Eli Lilly has spent years and billions of dollars in search of an effective Alzheimer's drug. But success is not all or nothing for the stock
▼ + stars: | 2023-01-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +22 min

Eli Lilly (LLY) has spent decades researching Alzheimer's disease without successfully bringing to market a treatment that slows the memory-destroying condition. For Eli Lilly as a company, an Alzheimer's drug is an important pursuit. Lilly's Alzheimer's history Eli Lilly's "first real foray" into Alzheimer's came in the 1990s, according to Dr. John Sims, Eli Lilly's head of medical development for donanemab. Financial implications for Lilly LLY mountain 2021-10-08 The Club started a new position in Eli Lilly (LLY) in October 2021. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

☆ Jim Cramer's top 10 things to watch in the market Wednesday: Tech layoffs, bank double downgrade, opportunities in industrials
▼ + stars: | 2023-01-04 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Analysts lower their rating on the tech giant to neutral from buy and their price target to $250 per share from $300. Analysts also cut price target to $100 per share from $118. Analysts trim price target to $193 per share from $220. BofA raises Merck (MRK) rating to buy from neutral and price target to $130 per share from $110. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Jim Cramer's top 10 things to watch in the market Tuesday: Wages too high, China reopening
▼ + stars: | 2023-01-03 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Barclays raises price target on Club holding Eli Lily (LLY) by $5-per-share to $400. UBS downgrades PG & E (PCG) to neutral from buy, with a $17-per-share price target; just above where the stock closed Friday. Barclays raises Exxon Mobil (XOM) price target to $129 per share from $111; keeps overweight (buy) rating. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Wall Street names these 20 Club stocks as top picks for 2023. Here's the list and our takes
▼ + stars: | 2022-12-29 | by ( Paulina Likos | ) www.cnbc.com time to read: +16 min

Club take: We've pared back our position in AMD this year as the semicondcutor company worked through its inventory correction. The company has to do more in terms of managing its costs, but it will likely be a priority in 2023. Analysts described growth outlooks in these segments as "robust" and expect them to drive revenue growth and margin expansion. BofA calls the Club stock a "top tier operator" and expects the company to grow revenue in the coming year despite fears of an economic downturn. Analysts expect to see strong data center growth next year, a business they said could reach $20 billion by 2023.

☆ Here’s our third-quarter earnings report card for all the stocks in our portfolio
▼ + stars: | 2022-12-27 | by ( Zev Fima | ) www.cnbc.com time to read: +17 min

Third-quarter earnings season is finally behind us — and like the prior quarter, results were solid overall compared to analyst forecasts. Danaher (DHR) reported sales and earnings beats on the back of better-than-expected results in all three segments of the health technology company. While U.S. customer traffic was down in the quarter, management noted that it improved sequentially and improved throughout the quarter. Still the luxury hotel and casino company reported solid third-quarter results boosted by its U.S. properties. Amazon (AMZN) reported results that were disappointing, to say the least, and compounded by guidance that was even worse.

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Hostess, Home Depot, Rivian, Netflix & more
▼ + stars: | 2022-12-20 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are Tuesday's biggest calls on Wall Street: Atlantic Equities names Coca-Cola as a top 2023 pick Atlantic Equities said it sees "category momentum" for shares of the beverage giant. JPMorgan reiterates Apple as overweight JPMorgan cut its price target on Apple to $190 per share from $200 due to supply chain challenges concerns. JPMorgan names Amazon as a top 2023 pick JPMorgan said Amazon is the "most diversified mega-cap across revs/profit & has numerous large growth opportunities." JPMorgan resumes DuPont as overweight JPMorgan resumed coverage of the stock and said it sees several positive catalysts ahead. JPMorgan names Bank of America a top 2023 pick JPMorgan said it likes the stock due to a "lower share of nonprime consumer loans."

☆ Jim Cramer's Investing Club meeting Monday: Industrials, buying tech, Eli Lilly
▼ + stars: | 2022-12-19 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Still bullish on Eli Lilly The Food and Drug Administration (FDA) added Eli Lilly 's (LLY) new type-2 diabetes drug Mounjaro to its list of drugs in short supply , highlighting strong demand for the medication. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Jim Cramer's top 10 things to watch in the market Friday: More selling, Estee Lauder, Meta Platforms
▼ + stars: | 2022-12-16 | by ( Jim Cramer | ) www.cnbc.com time to read: +3 min

Atlantic Equities expects growth at Club holding Estee Lauder (EL) to reaccelerate as China relaxes Covid restrictions. JPMorgan names AbbVie (ABBV) and Club holding Eli Lilly (LLY) as best in class and top picks in biopharma for 2023. Club holding Apple (AAPL) named a top tech pick at Evercore ISI. Barclays raises price target on General Electric (GE) to $96 per share from $92 ahead of the health-care spin-off. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ U.S. FDA flags shortage of Eli Lilly's new diabetes drug Mounjaro
▼ + stars: | 2022-12-16 | by ( ) www.reuters.com time to read: +1 min

[1/2] Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George FreyDec 16 (Reuters) - The U.S. health regulator has added Eli Lilly and Co's (LLY.N) Mounjaro to its list of drugs facing shortages, highlighting the company's struggles to meet booming demand for the newly approved diabetes injection. Trulicity, another diabetes treatment in the company's stable and its biggest-selling drug, was also added to the Food and Drug Administration's shortage list on Thursday. The company anticipates the drug, which has the common name tirzepatide, to get nod for obesity, an even bigger market, next year. Supply problems have also plagued a rival obesity drug, Wegovy, from Novo Nordisk (NOVOb.CO), although the Danish drugmaker is also working on boosting manufacturing capacity.

☆ Jim Cramer's top 10 things to watch in the market Thursday: Fed selling, chip stocks boost, Disney concern
▼ + stars: | 2022-12-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Barclay's raises price target on Club holding Wynn Resorts (WYNN) to $95 per share from $75; keeps an equal weight (hold) rating. Citi raises price target on Club holding Linde (LIN) to $402 per share from $322; keeps buy rating. HSBC starts Club stock Nvidia (NVDA) with a reduce rating and a $136-per-share price target; says downside not priced in. Cowen downgrades JetBlue (JBLU) to market perform from outperform (hold from buy); trims price target to $10 per share from $9. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Here's our November rapid-fire update on all 33 stocks in Cramer's Charitable trust portfolio
▼ + stars: | 2022-12-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

Here's a rapid-fire update on every stock in the CNBC Investing Club portfolio. Estee Lauder (EL) — New Club members who want to start a position in the cosmetics giant could do so at these levels. We'd advise Club members do so the same, even if we still like the company's defensive nature. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Jim Cramer's Investing Club meeting Wednesday: Fed decision, Qualcomm, Eli Lilly
▼ + stars: | 2022-12-14 | by ( Krystal Hur | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Don't trade on Fed decision Stay cautious on QCOM Stick with Eli Lilly 1. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Jim Cramer's Investing Club meeting Tuesday: Inflation cools, stock trim, Eli Lilly
▼ + stars: | 2022-12-13 | by ( Krystal Hur | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Wait to buy Eli Lilly Eli Lilly (LLY) said Tuesday it expects 2023 revenue to grow ahead of Wall Street expectations. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Dow has worst week since September as investors look ahead to CPI, Fed meeting
▼ + stars: | 2022-12-09 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

The next day, Fed Chair Jerome Powell is set to announce a decision on the next stage of rate hikes. But what's still a question mark is how high the Fed will take rates up, and for how long, given the current economic slowdown. The yield on the 10-Year Treasury moved higher this week amid renewed expectations the Fed will need to raise interest rates higher than expected. ET: Consumer price index FOMC meeting begins Wednesday, December 14 After the bell: Lennar (LEN), Trip.com (TCOM) FOMC meeting ends; rate decision at 2 p.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Here's where we stand after this week's big back-to-back market declines
▼ + stars: | 2022-12-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

We plan to update the Investing Club with some new additions in the coming days. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. The Dow Jones opened low this morning continuing its downward trend dipping more than 400 points as the stock market closed on Monday.

☆ Jim Cramer's Investing Club meeting Monday: Trimming oil, Starbucks, Eli Lilly
▼ + stars: | 2022-12-05 | by ( Krystal Hur | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Trimming HAL SBUX downgrade LLY opportunity? As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ December tends to be a strong month for the market. Here's how our stocks have done recently
▼ + stars: | 2022-12-05 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

So thought we'd look at what the Santa Claus rally phenomenon is all about and which Club stocks have had the best and worth December track records in recent years. It's a seven-day stretch over which the S & P 500 has historically tended to climb. The entire month of December has actually proven to be a historically strong period for the stock market. Investors would surely welcome a strong December after a terrible 11 months for the stock market. The S & P 500 tanked more than 9% that December, which at the time was its worth monthly performance in nearly a decade.

☆ What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly
▼ + stars: | 2022-11-30 | by ( ) www.cnbc.com time to read: +6 min

Donanemab is the name of Eli Lilly's Alzheimer's drug in its own late-stage trials. JPMorgan has a neutral (hold) rating on Biogen shares and an overweight (buy) rating on Eli Lilly shares. What it means for Eli Lilly Eli Lilly has a phase three trial underway for its donanemab Alzheimer's drug that is similar to lecanemab, which is why the Biogen-Eisai data has been interpreted as favorable for the Club holding. Clumps of the protein, known as amyloid plaques, are one of the key markers of Alzheimer's disease. Previous drugs developed around the a-beta hypothesis — including those from Eli Lilly — have failed to meaningfully delay the disease's progression.

☆ Jim Cramer's top 10 to watch Wednesday: Fed's Powell, Alzheimer's data
▼ + stars: | 2022-11-30 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Club holding Salesforce (CRM) is set to report fiscal third-quarter 2023 financial results after the closing bell Wednesday. Atlantic Equities says there's "no easy fix" at Club holding Disney (DIS) for returning CEO Bob Iger. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Rare success for Alzheimer's research unlocks hope for future therapies
▼ + stars: | 2022-11-29 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +6 min

Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. Lecanemab’s success rests on years of research into the causes of Alzheimer’s as well as advances in measuring amyloid deposits through brain scans and spinal fluids. At least 16 treatments are being tested in clinical trials, with results expected over the next three years, according to a Reuters review of the clinicaltrials.gov registry. The drugmaker has been largely absent from the Alzheimer's space after the high-profile failure of its drug verubecestat five years ago. But several antibody therapies from Lilly, Biogen and AbbVie(ABBV.N) that were designed to slow the rate of tau accumulations failed outright last year.

☆ How we're thinking about our Club stock exposure to China following Covid protests
▼ + stars: | 2022-11-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Global stocks slumped Monday on growing concerns about intensifying protests across China over the communist government's strict Covid policies. Apple (AAPL) — Revenue from China : 17.7% (China is the iPhone maker's second-largest market, lagging just the U.S. at 37.5% of sales.) Disney (DIS) — Revenue from China: 4.8% Devon Energy (DVN) — Revenue from China: 0% Estee Lauder (EL) — Revenue from China: 29.7% (China is the cosmetic giant's largest sales market, followed by the U.S. at 19.8%, per FactSet.) Ford Motor (F) — Revenue from China: 4.6% Alphabet (GOOGL) — Revenue from China: 3.8% Halliburton (HAL) — Revenue from China: 1.6% Honeywell International (HON) — Revenue from China: 4.2% Humana (HUM) — Revenue from China: 0% Johnson & Johnson (JNJ) — Revenue from China: 3.1% Eli Lilly (LLY) — Revenue from China: 5.7% Linde (LIN) — Revenue from China: 8.1% Meta Platforms (META): Revenue from China: 2.6% Morgan Stanley (MS) — Revenue from China: 2.6% Microsoft (MSFT) — Revenue from China: 12.4% Nvidia (NVDA) — Revenue from China: 25.8% — keep in mind: Nvidia's revenue is not attributed to the country in which the consumer buys a product that contains one of the company's semiconductors. Procter & Gamble (PG) — Revenue from China: 13.7% (China is P & G's second-largest sales market, with the U.S. accounting for 45.5% of revenue).

☆ Big Pharma will muscle in on obesity gold rush
▼ + stars: | 2022-11-28 | by ( Aimee Donnellan | ) www.reuters.com time to read: +4 min

LONDON, Nov 28 (Reuters Breakingviews) - Obesity drugs are a modern day gold rush for drugmakers. By then, the obesity market could total $50 billion, according to Morgan Stanley. But a plausible 50% price cut would lower annual sales to $25 billion. Reuters GraphicsFollow @aimeedonnellan on TwitterCONTEXT NEWSSales of Novo Nordisk’s obesity drugs Wegovy and Saxenda reached nearly $1.2 billion in 2021, up 50% versus the previous year. Morgan Stanley analysts expect the obesity market to grow to $50 billion in annual sales by 2030.

Search resuls for: "LLY"

25 mentions found